Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Psychogenics Picks Up Alzheimer’s Animal Model From USF

PsychoGenics obtained an exclusive license from the University of South Florida to its APP/PS1 double transgenic mice, which co-express the M146L presenilin 1 (PS1) mutation and the double mutations at K670N/M671L (Swedish mutation) in the amyloid precursor protein (APP).

22 Aug 2013

Cellectricon to discuss phenotypic assay designs for chronic pain research in webinar

Cellectricon, a leading provider of advanced cell-based screening technologies and services, invites researchers to join the webinar entitled “Phenotypic Screening Strategies for Chronic Pain Research”, taking place on 5 September, 11:00 am to 12:00pm EDT.

From Cellectricon 21 Aug 2013

Over 1,700 new chiral HPLC/SFC applications added to Phenomenex’s online resource

Phenomenex Inc., a global leader in the research and manufacture of advanced technologies for the separation sciences, announces the addition of over 1,700 new chiral HPLC/SFC applications to its online resource, including more than 400 new SFC (supercritical fluid chromatography) methods. Phenomenex’s extensive chiral application database is unique in the industry, particularly with the addition of the SFC methods, which were developed in collaboration with the Department of Analytical Chemistry and Pharmaceutical Technology, Vrije Universiteit Brussel, Brussels, Belgium.

19 Aug 2013

Researchers develop new method that creates libraries of drug candidates, accelerate drug discovery

James Bond had his reasons for ordering his martinis "shaken, not stirred." Similarly, drug manufacturers need to make sure the molecules in a new drug are arranged in an exact manner, lest there be dire consequences. Specifically, they need to be wary of enantiomers, mirror-image molecules composed of the same atoms, but arranged differently.

16 Aug 2013

New treatment technique uses nanoparticles to attack cancer

Researchers at the University of Georgia are developing a new treatment technique that uses nanoparticles to reprogram immune cells so they are able to recognize and attack cancer. The findings were published recently in the early online edition of ACS Nano.

16 Aug 2013

Sanford-Burnham, Pfizer collaborates to identify therapeutic targets for treating obesity, diabetes

Sanford-Burnham Medical Research Institute (Sanford-Burnham) announced that it has entered into a collaboration with Pfizer Inc. to identify new therapeutic targets for preventing and treating complications of obesity and diabetes.

14 Aug 2013

DNDi and Institut Pasteur Korea collaborates to spur fight against neglected diseases

A collaboration between the Drugs for Neglected Diseases Initiative (DNDi) and the Institut Pasteur Korea (IP-K) to spur the fight against neglected diseases has been established.

14 Aug 2013

Nuevolution forms scientific collaboration to investigate biological mechanism of GPCR drug target

Nuevolution A/S today announced that it has entered into a scientific collaboration with Duke University, the Howard Hughes Medical Institute, and Lexicon Pharmaceuticals, Inc. for the investigation of the biological mechanism of action of a specified GPCR drug target.

13 Aug 2013

Ensemble Therapeutics initiates research and development collaboration with Novartis

Ensemble Therapeutics, a biotechnology company developing Ensemblins, a novel class of small molecule therapeutics with the power of biologics, today announced the initiation of a two-part research and development collaboration with Novartis.

6 Aug 2013

Bayer Collaboration Could Net $540M+ For Compugen

...

6 Aug 2013

Compugen, Bayer sign collaboration and license agreement for antibody-based cancer immunotherapies

Compugen Ltd. announced today the signing of a collaboration and license agreement for the research, development, and commercialization of antibody-based therapeutics for cancer immunotherapy against two novel Compugen discovered immune checkpoint regulators.

5 Aug 2013

New findings could enable development of effective drugs for addiction with fewer side effects

Scientists from the Florida campus of The Scripps Research Institute have described findings that could enable the development of more effective drugs for addiction with fewer side effects.

3 Aug 2013

Thermo Fisher Scientific opens cell culture DPM production site in Singapore

Thermo Fisher Scientific Inc., the world leader in serving science, today announced it is expanding its global cell culture and bioprocessing capabilities by opening a new manufacturing plant in Singapore to produce dry powder media, a crucial cell culture raw material used to manufacture biologics, including vaccines, anti-cancer therapeutics, and others.

2 Aug 2013

Researchers show that JQ1 drug can block molecular pathway responsible for heart failure

Researchers from Case Western Reserve University School of Medicine and the Dana-Farber Cancer Institute have made a fundamental discovery relevant to the understanding and treatment of heart failure - a leading cause of death worldwide. The team discovered a new molecular pathway responsible for causing heart failure and showed that a first-in-class prototype drug, JQ1, blocks this pathway to protect the heart from damage.

2 Aug 2013

New NIH projects to target Fragile X syndrome, nicotine addiction and AMD

The National Institutes of Health has launched three innovative projects that will focus on development of therapeutics for Fragile X syndrome, nicotine addiction, and age-related macular degeneration. These projects are funded through the NIH Blueprint Neurotherapeutics Network which provides access to a variety of drug development resources.

1 Aug 2013

Researchers discover solution to long-standing medical mystery in Huntington's disease

Researchers at McMaster University have discovered a solution to a long-standing medical mystery in Huntington's disease (HD). HD is a brain disease that can affect 1 in about 7,000 people in mid-life, causing an increasing loss of brain cells at the centre of the brain.

30 Jul 2013

PerkinElmer enhances Operetta imaging system to perform live cell assays with higher throughput

PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment, has announced enhancements for its Operetta® High Content Imaging System, designed to significantly improve the ability of scientists to perform live cell assays with higher throughput, to help foster a better understanding of normal and aberrant cellular behavior.

25 Jul 2013

Scientists to explore student-driven research model for Distributed Drug Discovery

Purdue University Indianapolis (IUPUI) will host scientists from around the world next week for the first-ever workshop devoted to Distributed Drug Discovery, an innovative, student-driven research program quickly becoming a high-impact, low-cost teaching model.

20 Jul 2013

Research collaboration to tackle multiple sclerosis, motor neurone disease

Research into multiple sclerosis and motor neurone disease is to be boosted with an international collaboration to further understanding of these illnesses.